A Phase 3 Study of PBF-1681 Comprising a 16-week, Placebo-controlled, Double-blind Randomized Period and an 8-week, Open-label Extension Period for the Treatment of Iron Deficiency Anemia in Patients With Non-Dialysis Dependent CKD
Latest Information Update: 10 Mar 2023
At a glance
- Drugs Ferric citrate (Primary)
- Indications Iron deficiency anaemia
- Focus Registrational; Therapeutic Use
- Sponsors Panion & BF Biotech
- 07 Mar 2023 Status changed from recruiting to completed.
- 06 Mar 2022 Planned End Date changed from 1 Mar 2022 to 1 Jan 2023.
- 06 Mar 2022 Planned primary completion date changed from 1 Nov 2021 to 1 Jan 2023.